Literature DB >> 9823772

The role of IL-5 in bleomycin-induced pulmonary fibrosis.

M Gharaee-Kermani1, B McGarry, N Lukacs, G Huffnagle, R W Egan, S H Phan.   

Abstract

Eosinophils are known to express cytokines capable of promoting fibrosis. Interleukin-5 (IL-5) is important in regulating eosinophilopoiesis, eosinophil recruitment and activation. Lung IL-5 expression is elevated in pulmonary fibrosis, wherein the eosinophil is a primary source of fibrogenic cytokines. To determine the role of IL-5 in pulmonary fibrosis, the effects of anti-IL-5 antibody were investigated in a model of bleomycin-induced pulmonary fibrosis. Fibrosis was induced in mice by endotracheal bleomycin treatment. Animals were also treated with either anti-IL-5 antibody or control IgG. Lungs were then analyzed for fibrosis, eosinophil influx, chemotactic activity, and cytokine expression. The results show that a primary chemotactic activity at the height of eosinophil recruitment is IL-5. Furthermore, anti-IL-5 antibody caused significant reduction in lung eosinophilia, cytokine expression, and fibrosis. These findings taken together suggest an important role for IL-5 in pulmonary fibrosis via its ability to regulate eosinophilic inflammation, and thus eosinophil-dependent fibrogenic cytokine production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823772     DOI: 10.1002/jlb.64.5.657

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  17 in total

1.  Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis.

Authors:  Felipe Grabarz; Cristhiane Favero Aguiar; Matheus Correa-Costa; Tárcio Teodoro Braga; Meire I Hyane; Vinícius Andrade-Oliveira; Maristella Almeida Landgraf; Niels Olsen Saraiva Câmara
Journal:  Inflammopharmacology       Date:  2017-08-04       Impact factor: 4.473

Review 2.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

3.  Gender-based differences in bleomycin-induced pulmonary fibrosis.

Authors:  Mehrnaz Gharaee-Kermani; Kazuo Hatano; Yasuhiro Nozaki; Sem H Phan
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

4.  Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis.

Authors:  M R Hussein; H I Hassan; E R M Hofny; M Elkholy; N A Fatehy; A E A Abd Elmoniem; A M Ezz El-Din; O A Afifi; H G Rashed
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

5.  Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection.

Authors:  A Le Moine; V Flamand; F X Demoor; J C Noël; M Surquin; R Kiss; M A Nahori; M Pretolani; M Goldman; D Abramowicz
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

6.  Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.

Authors:  Francois Huaux; M Gharaee-Kermani; Tianju Liu; Valérie Morel; Bridget McGarry; Matt Ullenbruch; Steven L Kunkel; Jun Wang; Zhou Xing; Sem H Phan
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

Review 7.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 8.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy.

Authors:  Mehrnaz Gharaee-Kermani; Margaret R Gyetko; Biao Hu; Sem H Phan
Journal:  Pharm Res       Date:  2007-03-01       Impact factor: 4.580

Review 9.  Interstitial fibrosis and growth factors.

Authors:  J A Lasky; A R Brody
Journal:  Environ Health Perspect       Date:  2000-08       Impact factor: 9.031

10.  Bleomycin-Treated Chimeric Thy1-Deficient Mice with Thy1-Deficient Myofibroblasts and Thy-Positive Lymphocytes Resolve Inflammation without Affecting the Fibrotic Response.

Authors:  Pazit Y Cohen; Raphael Breuer; Philip Zisman; Shulamit B Wallach-Dayan
Journal:  Mediators Inflamm       Date:  2015-08-02       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.